<DOC>
	<DOCNO>NCT00527423</DOCNO>
	<brief_summary>Rollover study subject prior VEGF Trap-Eye Phase I II study . Primary objective ass long-term safety tolerability continue intravitreal treatment subject wet age-related macular degeneration .</brief_summary>
	<brief_title>Randomized , Single-Masked , Long-Term , Safety Tolerability Study VEGF Trap-Eye AMD</brief_title>
	<detailed_description>Randomized , Single-Masked Phase II study subject previously enrol Phase I II study wet age-related macular degeneration VEGF Trap-Eye intravitreal injection treatment.Long term ( 3 year ) treatment intend measure safety tolerability , well frequency re-treatment effect VEGF Trap-Eye best correct visual acuity ( BCVA ) .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Prior participation VEGF TrapEye Phase I II study Any ocular systemic adverse event would preclude participation Presence condition would jeopardize subject 's participation</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>VEGF Trap-Eye</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>AMD</keyword>
	<keyword>Neovascular Age-Related Macular Degeneration</keyword>
</DOC>